Medical Devices

63 tickers in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
DexCom, Inc.
DXCM·Healthcare
A ★★★★Buy
Current$82.29
Target$95.20
Return+15.7%
Nov 1, 2026

Dexcom offers recurring CGM revenue, high capital returns, and substantial long-term diabetes-monitoring growth potential at a compressed historical valuation, although Abbott competition and reimbursement constraints could limit upside.

Score
84
Agilent Technologies, Inc.
A·Healthcare
B ★★★Hold
Current$157.93
Target$172.64
Return+9.3%
Aug 29, 2026

Agilent is a high-quality, cash-generative tollbooth in life sciences and analytical instruments with rapid margin expansion, though investors must accept a steep valuation premium amid cyclical biotech capex headwinds and China trade risk.

Score
84
Insulet Corporation
PODD·Healthcare
A ★★★★Buy
Current$146.51
Target$170.94
Return+16.7%
Nov 7, 2026

Insulet combines recurring Omnipod revenue, strong international growth, and improving profitability with a sharply compressed valuation, although intensifying insulin pump competition and weaker cash conversion threaten future returns.

Score
83
ResMed Inc.
RMD·Healthcare
A ★★★★Buy
Current$229.94
Target$254.10
Return+10.5%
Nov 1, 2026

ResMed combines a durable sleep therapy franchise, recurring mask revenue, and high cash returns with a relatively attractive valuation, although evolving treatment alternatives and operating-margin pressure could constrain future earnings growth.

Score
83
Align Technology, Inc.
ALGN·Healthcare
A ★★★★Buy
Current$149.89
Target$195.20
Return+30.2%
Oct 31, 2026

Align Technology combines Invisalign's durable clinical franchise, strong cash flow, and attractive valuation with earnings recovery potential, although clear aligner price competition and weaker scanner demand could constrain growth.

Score
83
Globus Medical, Inc.
GMED·Healthcare
A ★★★★Buy
Current$71.05
Target$92.65
Return+30.4%
Nov 8, 2026

Globus Medical offers an attractive valuation backed by strong cash flow and a differentiated spine surgery ecosystem, but sustained upside depends on stabilizing Nevro demand and restoring underlying revenue growth.

Score
82
Teledyne Technologies Incorporated
TDY·Technology
A ★★★★Buy
Current$658.23
Target$742.50
Return+12.8%
Oct 31, 2026

Teledyne combines durable imaging and defense-electronics franchises with strong cash generation and growing demand, but premium valuation and acquisition integration risks limit its margin of safety.

Score
82
GE HealthCare Technologies Inc.
GEHC·Healthcare
A ★★★★Buy
Current$76.42
Target$84.63
Return+10.7%
Oct 30, 2026

GE HealthCare combines a durable medical imaging franchise with expanding diagnostics and software earnings at a moderate valuation, although acquisition integration and hospital capital spending cycles could constrain returns.

Score
82
Intuitive Surgical, Inc.
ISRG·Healthcare
A ★★★★Buy
Current$443.85
Target$460.56
Return+3.8%
Oct 23, 2026

Intuitive Surgical combines a dominant robotic-surgery ecosystem with recurring procedure revenue and strong cash generation, but its premium valuation and planned instrument-pricing reductions constrain near-term upside.

Score
82
Alcon Inc.
ALC·Healthcare
A ★★★★Buy
Current$71.83
Target$82.74
Return+15.2%
Nov 13, 2026

Alcon offers durable global eye-care demand, improving cash generation and a discounted historical valuation, but U.S. implant competition and weak reported capital efficiency could limit earnings growth.

Score
81
Stryker Corporation
SYK·Healthcare
A ★★★★Buy
Current$291.86
Target$338.10
Return+15.8%
Nov 1, 2026

Stryker combines a durable medical-device franchise, strong cash generation and a historically compressed valuation, but weaker guidance, cybersecurity exposure and acquisition impairments challenge near-term earnings confidence.

Score
81
Smith & Nephew plc
SNN·Healthcare
A ★★★★Buy
Current$31.15
Target$37.12
Return+19.2%
Nov 7, 2026

Smith & Nephew offers an attractive medical-device recovery opportunity supported by strong sports medicine franchises and improving cash generation, although persistent US orthopedic weakness and reimbursement pressure threaten execution.

Score
80